Gilead’s Trodelvy®Demonstrates Superior Outcomes in Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 Study
Gilead Sciences, Inc. announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy)
Read more